Potential utility of nano-based treatment approaches to address the risk of<i>Helicobacter pylori</i>

Khan, Samiullah; Sharaf, Mohamed; Ahmed, Ishfaq; Khan, Tehsin Ullah; Shabana, Samah; Arif, Muhammad; Kazmi, Syed Shabi Ul Hassan; Liu, Chenguang

doi:10.1080/14787210.2022.1990041

Cited by 13 publications

(11 citation statements)

References 193 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 23 KPCs are most commonly detected in K. pneumoniae from the US, China, Colombia, Israel, Greece, and Italy, according to Miao et al, whereas NDMs are mostly discovered in K. pneumoniae, E. coli, and Enterobacter spp. 24 , 25 …”

Section: Discussionmentioning

confidence: 99%

Detection of Carbapenem-resistance in CRE by Comparative Assessment of RAPIDEC® CARBA NP and Xpert™Carba-R Assay

El-Tahlawi¹,

Jiman-Fatani²,

Gad³

et al. 2023

IDR

View full text Add to dashboard Cite

Introduction Carbapenem-resistant Enterobacteriaceae (CRE) infections resist nearly most available antimicrobials, resulting in poor clinical outcomes. Saudi Arabia has a relatively high CRE prevalence. This study aims to evaluate the sensitivity of Rapidec Carba NP test and GeneXpert Carba-R assay compared with conventional manners for detection of carbapenemase-producing Enterobacteriaceae . Methods This is a cross-sectional study including a total of 90 CRE isolates examined at two tertiary hospitals in KSA from October 2020 to December 2021. Gram-negative Enterobacteriaceae were identified by using Vitek 2 system and were furtherly tested for imipenem and meropenem susceptibility by E- test strips, followed by Rapidec Carba NP test and the Xpert™Carba-R assay. Results Carbapenem-resistant K. pneumoniae (78.9%) and carbapenem-resistant E. coli (14.4%) were the two most common isolates species. Colistin (98.9%) and tigecycline (88.9%) were the most effective antibiotics against CRE isolates, followed by amikacin (52.2%), gentamicin (33.3%), cotrimoxazole (15.6%), and ciprofloxacin (8.9%). blaOXA-48 was the predominant carbapenemase gene (44.4%), followed by blaNDM (32.2%). blaKPC gene was not detected. The Rapidec Carba NP and the Xpert™Carba-R demonstrated an overall sensitivity of 69.3% and 88%, respectively, in comparison to gold standard detection of meropenem and imipenem resistance by Vitek 2 system and E- test strips. Discussion RAPIDEC ® CARBA NP may be a beneficial screening test for detecting CRE, but for confirmation of the results, Xpert Carba-R assay is more sensitive, significantly lowering the turnaround time compared to reference traditional methods. The information on carbapenemase genes may be used for epidemiologic purposes and outbreak management.

show abstract

Section: Discussionmentioning

confidence: 99%

Detection of Carbapenem-resistance in CRE by Comparative Assessment of RAPIDEC® CARBA NP and Xpert™Carba-R Assay

El-Tahlawi¹,

Jiman-Fatani²,

Gad³

et al. 2023

IDR

View full text Add to dashboard Cite

show abstract

“…In recent years, some novel therapies have brought benefits to patients with H. pylori . Some studies reported the potential of nanotechnology for H. pylori eradication ( de Souza et al, 2021 ; Khan et al, 2022 ). Nonetheless, clinical trials on this topic are still needed.…”

Section: Discussionmentioning

confidence: 99%

Jinghua Weikang capsule for helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis

et al. 2022

View full text Add to dashboard Cite

Background:Helicobacter pylori (H. pylori) infection is one of the most common chronic bacterial infections worldwide. The resistance of H. pylori to antibiotics may increase the risk of treatment failure. Complementary and alternative regimens are still needed. This study aimed to critically assess the efficacy and safety of Jinghua Weikang capsule (JWC) for H. pylori eradication.Materials and methods: PubMed, Embase, Web of Science, Cochrane library, China National Knowledge Infrastructure, Wanfang Digital Periodicals, and Chinese Science and Technology Periodicals database were searched from inception to April 2022. Randomized controlled trials (RCTs) comparing a combination of JWC and conventional treatments with conventional treatments alone or combined with a placebo for H. pylori eradication were considered for inclusion. The primary outcome was H. pylori eradication rate. The meta-analysis and trial sequential analysis (TSA) were conducted where possible.Results: A total of 34 studies were included in the statistical analysis. A pooled result showed that JWC with the duration of 2 weeks combined with the triple/quadruple therapy could significantly increase the H. pylori eradication rate compared with the triple/quadruple therapy alone (RR: 1.13, 95% CI: 1.05 to 1.21, p = 0.0008). However, the evidence of benefit was not confirmed by TSA. Another pooled result showed that JWC with the duration of 4 weeks combined with the triple/quadruple therapy could significantly increase the H. pylori eradication rate compared with the triple/quadruple therapy alone (RR: 1.21, 95% CI: 1.15 to 1.27, p < 0.00001). The evidence of benefit was confirmed by TSA. There were no statistically significant differences in the incidence of adverse reactions between the two groups.Conclusion: The present study suggests that JWC with the duration of 4 weeks can significantly improve the H. pylori eradication rate and should be considered as a complementary treatment to conventional regimens for H. pylori eradication. However, more high-quality RCTs are still needed to confirm these findings.

show abstract

“…Relying on the continuous movement of its flagellum, H. pylori penetrated and anchored on the epithelial cell surface of the gastric mucosa, not only effectively avoiding gastric acid erosion, but also significantly minimizing the effect of gastric emptying ( Saha et al, 2010 ). Conversely, most antibacterial drugs are less active or even inactivated in the extremely acidic environment of the stomach ( Khan et al, 2022 ). Even if not catabolized, regular gastric emptying diminishes the concentration of drug accumulation at the site of infection.…”

Section: Main Textmentioning

confidence: 99%

“…The physicochemical properties of biomaterials and their intended routes of delivery have the potential to be systematically tailored to maximize therapeutic efficacy ( Khan et al, 2022 ).…”

Section: Main Textmentioning

confidence: 99%

Application of biomaterials in the eradication of Helicobacter pylori: A bibliometric analysis and overview

Shu

Zhang²,

He³

et al. 2023

Front. Microbiol.

View full text Add to dashboard Cite

Helicobacter pylori is a prominent cause of gastritis, peptic ulcer, and gastric cancer. It is naturally colonized on the surface of the mucus layer and mucosal epithelial cells of the gastric sinus, surrounded not only by mucus layer with high viscosity that prevents the contact of drug molecules with bacteria but also by multitudinous gastric acid and pepsin, inactivating the antibacterial drug. With high-performance biocompatibility and biological specificity, biomaterials emerge as promising prospects closely associated with H. pylori eradication recently. Aiming to thoroughly summarize the progressing research in this field, we have screened 101 publications from the web of science database and then a bibliometric investigation was performed on the research trends of the application of biomaterials in eradicating H. pylori over the last decade utilizing VOSviewer and CiteSpace to establish the relationship between the publications, countries, institutions, authors, and most relevant topics. Keyword analysis illustrates biomaterials including nanoparticles (NPs), metallic materials, liposomes, and polymers are employed most frequently. Depending on their constituent materials and characterized structures, biomaterials exhibit diverse prospects in eradicating H. pylori regarding extending drug delivery time, avoiding drug inactivation, target response, and addressing drug resistance. Furthermore, we overviewed the challenges and forthcoming research perspective of high-performance biomaterials in H. pylori eradication based on recent studies.

show abstract

Potential utility of nano-based treatment approaches to address the risk ofHelicobacter pylori

Cited by 13 publications

References 193 publications

Detection of Carbapenem-resistance in CRE by Comparative Assessment of RAPIDEC® CARBA NP and Xpert™Carba-R Assay

Detection of Carbapenem-resistance in CRE by Comparative Assessment of RAPIDEC® CARBA NP and Xpert™Carba-R Assay

Jinghua Weikang capsule for helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis

Application of biomaterials in the eradication of Helicobacter pylori: A bibliometric analysis and overview

Contact Info

Product

Resources

About